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Abstract
Diabetes Mellitus, the metabolic syndrome where the body either fails to produce or effectively
utilize insulin, is associated with chronic morbidity.  While a definitive cure for the disease is
lacking, with the modern medicine offering mainly the means to control the extent of the disease,
Complementary and Alternative Medicine (CAMs) offers additional/alternate means to tackle the
disease. On the other hand, the lack of evidenced medical practices is a lacuna in most of the
traditional medical  applications.  Clerodendrum infortunatum.L (Lamiaceae family),  a perennial
shrub found in the tropics, has been known for its numerous pharmacological properties and is
found as a constituent in many Ayurvedic and Siddha drugs, especially for skin and respiratory
ailments. The plant has a noted potential as anti-hyperglycemic and has been found to be used in
traditional medicine for the treatment of diabetes. However, evidence based evaluations have not
been  conducted  on  the  anti-hyperglycemic  effect  of  the  plant,  especially  with  respect  to  the
general mode of intake,  i.e,  the aqueous form. In the current study, the aqueous extract of  C.
infortunatum  (CI),  was scientifically assessed for its effect on streptozotocin induced diabetes in
Wistar albino rats. The diabetic rats were divided into 5 groups of 6 animals each. For testing the
efficacy of extracts, two groups were intra-orally provided with dosages of 200 mg/Kg and 400 mg/
Kg  of  body  weight  of  animals,  respectively,  of  aqueous  extracts  of  CI.  Control  groups  were
maintained  for  evaluation,  which  included  vehicle  control  as  well  as  with  Glibenclamide,  a
standard anti-diabetic drug. The extracts at a dose of 400 mg/Kg body weight was found to be
associated with significant amelioration of many of the diabetes induced conditions, suggesting
that the plant extract could be a strong potential CAM candidate for therapeutic management of
diabetes.
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Introduction
Diabetes  mellitus  (simply  referred  diabetes),  a
metabolic disorder in which the body fails either
to  produce  or  to  respond  to  insulin  and  thus
resulting in faulty glucose metabolism, is a chronic
disease condition with a prevalence of 8.5% of the
world adult population (1). Diabetes type II is the
most  common,  responsible  for  90%  of  diabetes,
arises due to dysfunctional pancreatic beta cells or
impairment to insulin response by the body cells.
The  disorder  is  associated  with  morbidities  and
reduction in the quality of life and in addition, also
could  shorten  the  lifespan  due  to  complications
such as cardiovascular diseases (2).  There are no
curative  therapies  yet  identified  for  diabetes,
while management of the blood glucose levels by
restriction of sugar and calorie intake (especially
low glycemic index foods), regular monitoring of
blood sugar parameters, and more importantly by
adoption  of  healthy  lifestyle  (3),  in  an  optimal
manner have been shown to improve the quality
of life near normal. In chronic cases, the effective
management  of  type  2  diabetes  involves  insulin
therapy. However, the administration of the same
is fraught with difficulties such as the requirement
of a trained person for administration,  pain and
relative  cost.  Other  medicines  taken  orally
including  sulfonylureas  and  biguanides  have
limited  utility  and  are  also  fraught  with  side
effects.
Complementary  and  Alternative  Medicine
(CAM) offers some attractive means of managing
diabetes,  some of  which  uses herbal/plant  based
treatments (4). CAM has an added advantage that
some of the most populous countries in Asia and
Africa  have  a  ready  acceptability  for  traditional
therapeutic  systems.  Many of  the  CAM regimens
involve  components  of  plant  origin  which  are
known to be more bio tolerable  than chemically
synthesized agents. In addition, most of the CAMs
are relatively cheap compared to often proprietary
synthetic compounds, increasing the acceptability.
However, a major drawback with most CAM is that
while  many of  them are renowned,  the efficacy,
mode  of  action,  dosage  and side  effects  has  not
been extensively evaluated when compared to the
pharmaceutical agents of modern medicine. In the
current  study,  the  anti-hyperglycemic  properties
of  a  shrub,  Clerodendrum  infortunatum,  was
evaluated.
Clerodendrum infortunatum.L. is a perennial
shrub, with wide distribution noted in the tropical
regions of Asia, specifically of south Asia (5). The
English common name of the plant is ‘Hill  glory
bower’.  Various  parts  of  the  plant  find  uses  in
traditional medicine (6). Routine uses include use
as styptic and as anti-ascarid (7) while the tribes of
North-East  India  use  the  plant’s  extract  for
subsiding  fever  and  intestinal  diseases.  Some  of
the closely related species, C. serratum (8) referred
in  texts  of  Ayurveda  as  an  antidiabetic
(Madhumehagna)  , and  C.  phlomoides  shown  to
reduce fasting blood sugar in human subjects (9),
have  been  known  to  have  potent  anti-
hyperglycemic  properties.  While  anti-
hyperglycemic  effects  of  solvent  extracts  have
been  shown  for  C.  infortunatum (10),  the
traditional route of intake, aqueous decoction, has
not been evaluated. The objective of this study was
to assess the anti-diabetic activity of the aqueous
extracts  of  Clerodendrum  infortunatum.  L.  in
streptozotocin induced diabetes in rats.
Materials and methods
Plant material
C.  infortunatum was  collected  and  identified  as
correct  species  from  its  natural  habitat  at
Pandalam, Kerala, India. The species was verified
by  a  specimen  submitted  to  Jawharlal  Nehru
Tropical  Botanic  Garden  and  Research  Institute
(JNTBGRI), Thiruvananthapuram, Kerala.
The plant body (stem and leaves) were shade
dried in such a way that the weight of the dried
item remained same over 3 consecutive days.  50
grams of the dried material was weighed and was
finely ground in a mortar with the help of pestle.
The aqueous extract of CI was prepared by boiling
50  grams  of  dry  CI  powder  in  a  clean  round
bottom flask by boiling for  2 hours,  followed by
sieving the extract first with a sterile mesh cloth
and  subsequently  through  a  coarse  filter  paper.
The extract, devoid of visible solids, were allowed
to evaporate by gentle heating to leave thick slurry
in  the  end.  The  slurry  was  then  suspended  in
distilled water to get desired concentration as per
the dose (mg/kg body weight). Formulation of the
test item was prepared shortly before dosing. The
homogeneity  of  the  test  formulation  was
maintained by continuous stirring of the glass rod
during dosing.
Animal Studies 
The animal studies were conducted after obtaining
ethics committee approval and were conducted at
department of toxicology, CARe Keralam (Thrissur,
India).  Wistar  Albino  rats  (procured  from
Veterinary University, Thrissur, India) were used.
30 male rats were used during the conduct of the
study.  Animals  weighing between 200-250 grams
were  selected  for  the  treatment  at  the  age  of
between 12 to 14 weeks post birth.
Induction  of  diabetes  and  subsequent
treatment
Animals,  after  acclimatization  (5  days)  in  the
animal  house,  were  randomly  divided  into  five
groups of six animals.  Diabetes was induced using
streptozotocin (STZ) (Sigma-Aldrich Inc, Missouri,
USA), dissolved  in freshly prepared citrate buffer
(0.1  M,  pH  4.5)  and  administered  as
intraperitoneal.  Rats  previously  fasted  for  16  h
were given single intraperitoneal injection of 120
mg/kg  Nicotinamide  30  minutes  prior  to
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administration of 40 mg/kg body weight. Animals
with  fasting  blood  glucose  between  200  -250
mg/100  mL,  three  days  after  STZ  administration
were further selected for the study. Glibenclamide
(Sigma-Aldrich Inc, Missouri, USA) was used as the
standard antidiabetic drug and was administered
peri-orally  at  a  concentration  of  600  µg/Kg  body
weight.
The  groups  were  treated (Table  1) and
were monitored for 40 days. At the end of study all
the animals were sacrificed by cervical dislocation.
Wherever applicable,  distilled water was used as
control.
Table 1. The stratification of the animals into groups
and respective treatments
Category Treatment
Group-1 Vehicle control
Group-2 STZ only
Group-3 STZ + Glibenclamide 600 µg/Kg body weight
Group-4 STZ + CIE 200 mg/Kg body weight
Group-5 STZ + CIE 400 mg/Kg body weight
Administration of CI extract
Acute  oral  toxicity  studies  were  conducted  to
determine the toxicity against 500mg/Kg, 1gram/Kg
and 2gram/Kg body weight. No toxicity or adverse
responses were noted. Test doses were fixed at 200
and 400 grams (10% and 20% of upper test dose,
respectively). The extract, as well as the standard
anti-diabetic  drug  glibenclamide,  was
administered  orally  by  gavage  to  each  rat  as  a
single dose (as mentioned in Table 1), once daily,
for  a  period  of  40  days.  The  dosage  volume
administered  to  individual  rat  was  adjusted
according to its body weight recorded on the day
of dosing. The dose volume was 1 ml/100 g body
weight for all animals. Food was offered 3-4 hours
after dosing.
Biochemical analyses
Blood  samples  were  collected  by  the  tail-  vein
method and blood glucose levels were measured
immediately by using glucose oxidase- peroxidase
reactive  strips  and  a  glucometer.  Blood  samples
were  collected  on  days  0,  10,  20,  30  and  40,
respectively,  for this  purpose.  Additionally  blood
samples  were  collected  on  the  41st day  of
administration  and  were  allowed  to  clot  for  30
minutes. After that, the animals were sacrificed by
cervical dislocation for visceral inspection as well
as  necropsy  analysis.  Serum  separated  from the
blood  samples  were  used  for  the  estimation  of
biochemical  parameters  including  Alkalaine
phosphatase  (ALP),  Aspartate  amino  transferase
(AST), Alanine amino transferase (ALT), Bilirubin,
Serum  creatinine,  total  protein  and  plasma
insulin.  The biochemical  parameters  were tested
using commercially available kits and were done
as  per  manufacturer’s  protocols.  Plasma  insulin
was  determined  using  Chemiluminescent
Microparticle Immuno Assay. 
Statistical Analysis
The  data  of  all  the  parameters  were  analyzed
using  Analysis  of  variance  (ANOVA).  One  way
ANOVA followed by Dunnet's test was performed
in which the diabetic control was compared with
all the other groups and the values are expressed
in Mean ± SD.  Statistical analyses were conducted
using SPSS statistics version 13 software (IBM inc.,
USA). P-value less than 0.05 was considered to be
statistically significant.
Results
In order to identify the effect of C. infortunatum on
the  glucose  level  of  the  animals,  periodic
monitoring,  on  an  interval  of  10  days,  of  blood
glucose was performed (Fig. 1).  The reduction of
the  blood  glucose  levels  was  discernable  in
diabetes  induced  rats  from the  tenth  day  of  the
treatment  (in  both  CI  extracts  and  in
Glibenclamide treatment). Significant reduction of
the glucose levels were seen in C. infortunatum at
400 mg/kg dose (p<0.001), although not abrupt as
that  of  the  anti-diabetic  drug  glibenclamide  at
0.6mg/kg dose. However, at lower doses of CI (200
mg/kg), the reduction though noted, was not highly
statistically  significant.  The  reduction  in  the
elevated  blood  sugar  in  the  diabetic  rats  was
relatively slow in case of the extracts treated group
(in both doses). Glibenclamide, on the other hand
had a relatively fast paced action, wherein by the
thirtieth  day  of  the  study,  the  glibenclamide
treated diabetic rats had a closer-to-normal blood
glucose level.  The CI extract at 400 mg dose was
able  to  bring  down  the  glucose  in  a  gradual
manner,  with only a modest  reduction noted till
the 30th day (at 215 ± 12.88 mg/dL Vs. 126.67 ± 7.71
mg/dL  in  case  of  glibenclamide).  However,  a
stronger reduction in blood sugar level was noted
in the CI extract at 400 mg dose by day 40 (blood
sugar level at 175.67 ± 13.5 mg/dL). On the other
hand  the  low  dose  (CIE  200)  treatment  was  not
very effective in bringing down the sugar levels,
even at the end of the study (blood sugar level at
231.33 ± 12.48 mg/dL on the 40th day). 
Similarly,  there was significant elevation in
the serum insulin levels of the diabetic rats when
treated with CI extracts at 400 mg/kg body weight
(p<0.01) (Fig.  2). However,  at  lower  dose  of  the
extract, the inducements of insulin in diabetic rats
were only modest and were not significant. While
the  normal  (un-diabetic)  rats  had  an  average
serum  insulin  of  3.37  ±  0.56  µIU/mL,  a  drastic
reduction  in  serum  insulin  was  noted  in  the
diabetic  rats  (serum insulin  0.18  ±  0.08  µIU/mL)
indicating the extensive destruction of pancreatic
beta  cells  by  streptozotocin.  As  expected,
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glibenclamide induced the elevation of insulin to
the  maximal  levels  among  the  treatment  group,
with  the  insulin  production  measured  at  2.65  ±
0.58 µIU/mL by the 40th day.  The CI extracts at 400
mg/Kg dose could also improve the insulin levels;
however, the levels were not as much as that  of
glibenclamide (1.18 ± 0.39 µIU/mL in 400 mg dose
on 40th day). At the lower dose of 200 mg/Kg the
production of insulin could only be boosted to 0.45
± 0.24 µIU/mL and was not significant.
Next,  we  evaluated  the  liver  function
parameters  of  the  animals  to  ascertain  the
aftermath  of  anti-hyperglycemic  effect  of  the  CI
extracts on liver since liver function abnormalities
are usual in diabetes (especially with relevance to
the  gluconeogenesis  and ketone  body  synthesis).
We  ascertained  the  liver  function  by  evaluating
the  major  biochemical  indicators  of  liver
functions,  viz.  ALT,  AST,  ALP,  creatinine  and
bilirubin.  As expected, the inductions of diabetes
by  STZ  lead  to  significant  elevation  of  the
indicators when compared to the vehicle control
animals (Fig. 3).  In all the tested parameters, the
liver functions of the diabetes induced rats could
be  significantly  improved  by  CI  extracts.  CI
extracts  at  400  mg/kg  dose  could  significantly
lower the levels of the elevated liver parameters
(p<0.01  in  all  the  tested  parameters,  Fig.  3  and
Table  2),  although lower doses could not  exhibit
such  a  significant  reduction.  As  expected,
glibenclamide  treatment  could  also  significantly
lower the levels of the indicators (p<0.01, Fig. 3).
Discussion
The  usual  effects  of  diabetes  and  its  allied
pathophysiology are widespread. This involves not
only changes in the overall sugar metabolism, but
also  effects  on  the  functional  and  structural
integrity of the major organs including liver and
pancreas  (11).  For  management  of  diabetes  the
foremost importance is given to the upkeep of the
blood sugar levels within or close to the normal
physiological levels. For therapeutic management,
blood-sugar  lowering  drugs  such  as  metformin,
which  mainly  acts  by  decreasing  the  glucose
production  by  liver,  are  used  (3).  Some  of  the
drugs  also  increase  the  insulin  sensitivity.
Similarly, insulin inducing drugs (as secretogauge)
and drugs which enhance the insulin production
from beta-cells are also used. Exogenous insulin is
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Fig.  1.  Reduction  in  blood  glucose  levels  in  various  test
groups over the period of study (40 days). Glibenclamide and
CIE400  both  significantly  reduced  the  blood  sugar  levels
(p<0.001).
Fig. 2.  Plasma Insulin level measured on day 40. Significant
enhancement  in  insulin  production  was  observed  in
Glibenclamide  (p<0.001)  and  CIE400  (p<0.01).  ns  –  not
significant, STZ- streptozotocin, Gb –glibenclamide, CIE200 and CIE400
– cleorodendrum infortunatum extract 200 mg and 400 mg/kg doses
respectively.
Table 2. Biochemical parameters relevant to liver function.  (*p<0.1, **p<0.01, ***p<0.001)
Group Serum Creatinine (mg/dL) Serum Urea (mg/dL) Total protein (mg/dL)
I   -   Vehicle control 0.457±0.132*** 32.900±2.407*** 8.873±0.563***
II  - STZ only 1.537±0.120 64.367±4.030 4.343±0.429
III  - STZ + Glibenclamide 0.613±0.109*** 41.133±5.673*** 7.617±0.514***
IV - STZ + CI extract 200 mg/kg 1.452±0.284ns 60.733±7.184ns 4.723±0.695n
V  - STZ + CI extract 400 mg/kg 1.130±0.215** 50.950±7.074** 5.498±0.677**
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also given as hypodermic injection depending on
the severity of the disease. 
Complementary  and  Alternate  Medicine
(CAM)  also  offer  anti-diabetic  medications,
especially some of them, with components such as
fenugreek,  being  in  effective  use  for  many
centuries (12).  Some of the herbal medicines are
also made as formulations of multiple individual
components,  however,  even  when  the  effects  of
the  herbal  drugs  and  their  formulations  have
known physiological impact, details regarding the
mechanism  of  action  and  dosage  are  often  left
subjective (13). Furthermore, there is the need to
further explore alternative remedies which could
offer  more  potent  or  more  bio-tolerant
medications.
In the study, aqueous CI extracts could lower
the blood glucose in multitude of ways, which may
perhaps  be due to the synergistic effects exerted
by individual phytochemical components (14). The
improvement of glucose metabolism, as seen in the
progressive improvement in the blood glucose of
the animals over the period of study (Fig. 1), points
to  the  anti-hyperglycemic  potential  of  the  plant
extracts.  However,  when  compared  to  the
standard  drug  glibenclamide,  the  effects  were
more  gradual.  While  glibenclamide  could  bring
the  blood  glucose  levels  in  the  diabetic  animals
near  normal  within  30  days  (at  126.67  ±  7.71
mg/dL on 30th day), the blood glucose levels (even
though  significantly  reduced)  in  animals  treated
with  CI  extracts  at  400  mg/kg  was  still  at  an
elevated level on 40th day (at 175.67 ± 13.5 mg/dL
on 40th day) (Table S1).  This could be due to the
moderation  due  to  the  synergestic  effects  of
multiple  components (14),  unlike  single  agent
therapy  where  the  dose  is  optimized  for  rapid
action  of  one  component,  like  the  stimulated
release of insulin as in the current case  (15). There
was significant elevation in the blood insulin levels
in the animals treated at 400 mg/Kg dosage. This
was  comparable  to  the  effects  of  glibenclamide,
though  not  as  robust  as  that  of  the  latter.
Glibenclamide  is  known  to  induce  enhanced
production of  insulin from beta cells  (15).  When
compared  to  non-diabetic  animals  and  the
glibenclamide treated diabetic rats, the induction
of insulin by CI extract even at the maximum dose
400mg/kg was only modest (Fig. 2). Taken together,
it  is  possible  that  the  improvement  in  glucose
levels seen in the extract fed rats may be due to
the induction of insulin from pancreas. 
Indicating  the  multi-target  effect  of  the  CI
extracts, there was a marked improvement in the
liver function in the diabetic  rats,  as  assayed by
the  key  liver  enzymes.  At  400  mg/Kg  dose  the
improvement  in  liver  function  (as  per  tested
biochemical parameters) was significant and was
comparable  to  the  standard  drug  glibenclamide.
While the improvement in the liver function may
be due to the lowering of blood sugar, as was the
case with glibenclamide, it could be also possible
that  multiple  phytochemical  constituents  may be
conferring  protective  advantage  to  other  vital
organs such as liver (14). 
In  the  current  study,  we  observed  a  dose
dependency in the administration of drugs in the
amelioration  of  diabetic  pathology.  While  the
diabetic animals treated at lower dose (200 mg/kg)
exhibited  moderate  levels  of  improvement,
significant  improvement  was  conferred  by  the
extracts  at  higher  dose  (400  mg/Kg).  Further
optimization of the dose, as well as optimizing the
source plant materials may be useful in improving
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Fig. 3. Liver function parameters among the various test groups (*p<0.1, **p<0.01, ***p<0.001)
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the  efficacy  of  a  given  dose.  The  latter  is  more
important  as  it  is  a  well-known  fact  that
phytochemical constituents alter in the same plant
species  depending  on  the  climatic  conditions,
growth phase and altitude (16).  
There were previous attempts in identifying
the medicinal value of C. infortunatum. A previous
study (10)  using  methanolic  extracts  of  the  CI
(MECI)  leaves  on  male  Wistar  rats  identified  a
statistically  significant  improvement  in  the  STZ
induced  hyperglycemia.  However,  aqueous
extracts  may  be  a  better  alternative  to  organic
solvent based extraction in some ways.  First,  the
traditional  and  folkloric  use  of  plant  based
medicines  predominantly  utilizes  raw  juices,
water  extracts  and aqueous  decoctions.  Being in
use  over  centuries  by  the  traditional  medicine,
they offer quick preliminary checklist to pick from
while  identifying alternate  solutions to  therapies
for  complex  diseases.  However,  efficacy  and
dosage  is  often  vague  and  rarely  scientifically
evidenced  (16).  Aqueous  extracts  offer  high
similarity  with  the  traditional  applications.
Secondly,  organic  solvents  and their  by-products
left over from the extracting process are at times
toxic  and  their  direct  application  may  have
unintended  off-target  side-effects (17).  This  is
critical because complex diseases such as diabetes
may also weaken crucial organs such as liver; the
left over toxic solvents may be deleterious in such
conditions,  especially  because anti-diabetic  drugs
may have to be taken regularly and lifelong.
Conclusions
There  are  many  traditional  and  Ayurvedic
formulations  where  C.  infortunatum is  a
constituent. But none of them are targeted for anti-
diabetic  properties  of  the  plant  as  the  primary
goal. In the current study, we evaluated the anti-
diabetic  properties  of  the  aqueous  extract  of  C.
infortunatum on  diabetes-induced  Wistar  rats  at
two  doses,  viz. 200mg/Kg  and  400mg/Kg,  and
identified that 400mg/kg to have significant effect.
Improvement  in  blood  glucose  levels,  enhanced
insulin  production  and  improvements  in  liver
functions  were  noted  in  extract  treated  diabetic
rats  when  compared  to  the  untreated  diabetic
animals.  Further  investigation  in  the  medicinal
properties, optimal dose and toxicology is essential
so that the diabetic patients may be able to benefit
from the anti-diabetic  potential  of this  medicinal
plant.
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